Beatrix Bartók

3.6k total citations · 3 hit papers
40 papers, 2.7k citations indexed

About

Beatrix Bartók is a scholar working on Genetics, Rheumatology and Hematology. According to data from OpenAlex, Beatrix Bartók has authored 40 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 20 papers in Rheumatology and 17 papers in Hematology. Recurrent topics in Beatrix Bartók's work include Chronic Lymphocytic Leukemia Research (28 papers), Rheumatoid Arthritis Research and Therapies (19 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Beatrix Bartók is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), Rheumatoid Arthritis Research and Therapies (19 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Beatrix Bartók collaborates with scholars based in United States, Japan and Belgium. Beatrix Bartók's co-authors include Gary S. Firestein, F. Matzkies, Ying Guo, Chantal Tasset, John S. Sundy, Neelufar Mozaffarian, Mark C. Genovese, David L. Boyle, Tsutomu Takeuchi and Jacques‐Eric Gottenberg and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and The Journal of Immunology.

In The Last Decade

Beatrix Bartók

40 papers receiving 2.7k citations

Hit Papers

Fibroblast‐like synoviocytes: key effector cells in rheum... 2009 2026 2014 2020 2009 2019 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
    2009 1.5k citations Beatrix Bartók, Gary S. Firestein Immunological Reviews profile →
  2. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
    2019 224 citations Mark C. Genovese, Kenneth Kalunian et al. profile →
  3. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    2021 163 citations Bernard Combe, Alan Kivitz et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beatrix Bartók United States 17 1.3k 962 734 568 516 40 2.7k
Stefano Alivernini Italy 26 963 0.7× 876 0.9× 851 1.2× 305 0.5× 333 0.6× 85 2.6k
Hong Ji China 21 935 0.7× 1.8k 1.8× 1.9k 2.5× 930 1.6× 301 0.6× 35 4.1k
Hans P. Kiener Austria 29 803 0.6× 677 0.7× 700 1.0× 336 0.6× 209 0.4× 51 2.2k
Emmanuel Karouzakis Switzerland 20 558 0.4× 1.0k 1.1× 481 0.7× 279 0.5× 223 0.4× 30 1.9k
Jean‐Pierre David Germany 30 884 0.7× 2.8k 2.9× 840 1.1× 1.4k 2.4× 182 0.4× 48 4.2k
M Tohidast-Akrad Austria 18 1.2k 0.9× 1.4k 1.5× 491 0.7× 851 1.5× 206 0.4× 31 2.5k
C. Pecquet France 30 351 0.3× 960 1.0× 247 0.3× 365 0.6× 936 1.8× 91 2.5k
Akeila Bellahcène Belgium 37 1.0k 0.8× 2.4k 2.5× 412 0.6× 1.7k 2.9× 84 0.2× 67 4.5k
Seung‐Ah Yoo South Korea 27 447 0.3× 881 0.9× 446 0.6× 291 0.5× 137 0.3× 57 1.8k
Stephen Breit Germany 22 310 0.2× 1.4k 1.4× 160 0.2× 295 0.5× 229 0.4× 30 2.5k

Countries citing papers authored by Beatrix Bartók

Since Specialization
Citations

This map shows the geographic impact of Beatrix Bartók's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatrix Bartók with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatrix Bartók more than expected).

Fields of papers citing papers by Beatrix Bartók

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatrix Bartók. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatrix Bartók. The network helps show where Beatrix Bartók may publish in the future.

Co-authorship network of co-authors of Beatrix Bartók

This figure shows the co-authorship network connecting the top 25 collaborators of Beatrix Bartók. A scholar is included among the top collaborators of Beatrix Bartók based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatrix Bartók. Beatrix Bartók is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Combe, Bernard, Yoshiya Tanaka, Maya H Buch, et al.. (2022). Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study. Rheumatology and Therapy. 10(1). 53–70. 5 indexed citations
2.
3.
Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2021). Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases. 80(7). 848–858. 163 indexed citations breakdown →
4.
Aletaha, Daniel, René Westhovens, C. Gaujoux-Viala, et al.. (2021). Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD Open. 7(2). e001621–e001621. 14 indexed citations
5.
Winthrop, Kevin, Yoshiya Tanaka, Tsutomu Takeuchi, et al.. (2021). Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases. 81(2). 184–192. 62 indexed citations
6.
Besuyen, R., Mark C. Genovese, Kurt de Vlam, et al.. (2020). P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs. Journal of Crohn s and Colitis. 14(Supplement_1). S350–S352. 1 indexed citations
7.
Genovese, Mark C., Kevin Winthrop, Yoshiya Tanaka, et al.. (2020). THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS. Annals of the Rheumatic Diseases. 79. 324–325. 11 indexed citations
8.
Walker, David, Bernard Combe, Yoshiya Tanaka, et al.. (2020). P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. Lara D. Veeken. 59(Supplement_2). 1 indexed citations
9.
Takeuchi, Tsutomu, Tsukasa Matsubara, Tatsuya Atsumi, et al.. (2020). Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). Modern Rheumatology. 32(1). 59–67. 8 indexed citations
10.
Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2019). Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results. Queensland's institutional digital repository (The University of Queensland). 71. 16 indexed citations
11.
Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2019). LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. Annals of the Rheumatic Diseases. 78. 77–78. 25 indexed citations
12.
13.
Whitaker, John W., David L. Boyle, Beatrix Bartók, et al.. (2015). Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic Targets. PLoS ONE. 10(4). e0124254–e0124254. 45 indexed citations
14.
Stanford, Stephanie M., German R. Aleman Muench, Beatrix Bartók, et al.. (2014). TGFβ responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness. Annals of the Rheumatic Diseases. 75(1). 295–302. 33 indexed citations
15.
Stanford, Stephanie M., Amanda M. Campbell, Beatrix Bartók, et al.. (2013). Protein Tyrosine Phosphatase Expression Profile of Rheumatoid Arthritis Fibroblast‐like Synoviocytes: A Novel Role of SH2 Domain–Containing Phosphatase 2 as a Modulator of Invasion and Survival. Arthritis & Rheumatism. 65(5). 1171–1180. 43 indexed citations
16.
Bartók, Beatrix, David L. Boyle, Yi Liu, et al.. (2012). PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis. American Journal Of Pathology. 180(5). 1906–1916. 87 indexed citations
17.
Bartók, Beatrix & Gregg J. Silverman. (2011). Development of anti-CD20 therapy for multiple sclerosis. Experimental Cell Research. 317(9). 1312–1318. 7 indexed citations
18.
Bartók, Beatrix & Gary S. Firestein. (2009). Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis. Immunological Reviews. 233(1). 233–255. 1527 indexed citations breakdown →
19.
Felice, Maria Rosa, Ivana De Domenico, Liangtao Li, et al.. (2005). Post-transcriptional Regulation of the Yeast High Affinity Iron Transport System. Journal of Biological Chemistry. 280(23). 22181–22190. 89 indexed citations
20.
Sozio, Margaret S., Jennifer A. Young, Sébastien Wälchli, et al.. (2004). PTPH1 Is a Predominant Protein-tyrosine Phosphatase Capable of Interacting with and Dephosphorylating the T Cell Receptor ζ Subunit. Journal of Biological Chemistry. 279(9). 7760–7769. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefano Alivernini Breakdown of academic impact, for papers by Hong Ji Breakdown of academic impact, for papers by Hans P. Kiener Breakdown of academic impact, for papers by Emmanuel Karouzakis Breakdown of academic impact, for papers by Jean‐Pierre David Breakdown of academic impact, for papers by M Tohidast-Akrad Breakdown of academic impact, for papers by C. Pecquet Breakdown of academic impact, for papers by Akeila Bellahcène Breakdown of academic impact, for papers by Seung‐Ah Yoo Breakdown of academic impact, for papers by Stephen Breit
Rankless by CCL
2026